top of page
  • Writer's pictureMynd Life Sciences

MYND Life Sciences to Present at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Confe

VANCOUVER, BC, June 15, 2021 /PRNewswire/ – MYND Life Sciences Inc. (CSE: MYND) (“MYND“) a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, is pleased to announce that CEO, Dr. Lyle Oberg, will be presenting at the “Psychedelics in Psychiatry and Beyond” conference sponsored by H.C. Wainwright & Co.

The conference will be held virtually on Thursday, June 17, 2021. Dr. Oberg will provide an overview of MYND’s business, intellectual property holdings and its pipeline towards both a novel diagnostic and drug innovation for treating and diagnosing depression and other diseases of neuroinflammation.

Details of the presentation are as follows:


 Thursday, June 17th, 2021


 MYND’s presentation will be available to access beginning at 9:30EDT


For more information and to subscribe to the Company’s mailing list, please visit


MYND Life Sciences is a psychedelic medicine biotech company focused on neuro-pharmaceutical drug development. The Company is advancing psychedelic-derived medicines based on neuro-anti-inflammatory substances through rigorous science and clinical trials with an initial focus on Major Depressive Disorder.


Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.  

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

SOURCE Mynd Life Sciences Inc.


bottom of page